<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="996705c7-5da7-4539-8bf3-36efe8e9f51a"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">HIGHLIGHTS OF PRESCRIBING INFORMATION<br/>
These highlights do not include all the information needed to use FLUOCINOLONE ACETONIDE 0.01% TOPICAL OIL safely and effectively. See full prescribing information for FLUOCINOLONE ACETONIDE 0.01% TOPICAL OIL.<br/>
      </content>
      <content styleCode="bold">FLUOCINOLONE ACETONIDE 0.01% Topical Oil, Body Oil, f</content>
      <content styleCode="bold">or topical useÂ <br/>
      </content>
      <content styleCode="bold">Initial U.S. Approval: 1988</content>
   </title>
   <effectiveTime value="20250519"/>
   <setId root="64586ff9-941a-418a-a870-ffb5dafbe24b"/>
   <versionNumber value="15"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="123797875" root="1.3.6.1.4.1.519.1"/>
            <name>Amneal Pharmaceuticals LLC</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="b28b9441-9fb5-4927-b6d9-87b036934591"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250519"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="65162-704" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>FLUOCINOLONE ACETONIDE</name>
                        <formCode code="C42965" displayName="OIL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>FLUOCINOLONE ACETONIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.11"/>
                              <denominator unit="mL" value="118.28"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0CD5FD6S2M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FLUOCINOLONE ACETONIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="0CD5FD6S2M" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FLUOCINOLONE ACETONIDE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ND2M416302" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0RE8K4LNJS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL MYRISTATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="N6K5787QVP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LIGHT MINERAL OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7L6R1SQ6M0" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OLETH-2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5TL50QU0W4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PEANUT OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="118.28"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="65162-704-86" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20150922"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA201764" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20150922"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" displayName="yellow" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" displayName="TOPICAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_cc924eef-bc6d-4841-a155-0ab69f4ca5e8">
               <id root="c50daa8d-18a3-4cce-8e1a-1a3e4345ecfb"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Fluocinolone Acetonide 0.01% Topical Oil (Body Oil) is indicated for the topical treatment of: </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>atopic dermatitis in adults</item>
                     <item>moderate to severe atopic dermatitis in pediatric patients 3 months of age and older</item>
                  </list>
               </text>
               <effectiveTime value="20250519"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Fluocinolone Acetonide 0.01% Topical Oil (Body Oil) is a corticosteroid indicated for the topical treatment of:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>atopic dermatitis in adults (<linkHtml href="#LINK_cc924eef-bc6d-4841-a155-0ab69f4ca5e8">1</linkHtml>)</item>
                           <item>moderate to severe atopic dermatitis in pediatric patients 3 months of age and older (<linkHtml href="#LINK_cc924eef-bc6d-4841-a155-0ab69f4ca5e8">1</linkHtml>)</item>
                        </list>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_347c7ceb-a97c-4b66-8f7a-9c62367a60a6">
               <id root="4655c31b-6af4-4dcf-891c-eeaa9e521c4f"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <br/>
               </text>
               <effectiveTime value="20250519"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Fluocinolone acetonide 0.01% topical oil is not for oral, ophthalmic, or intravaginal use. (<linkHtml href="#LINK_702a56b6-b0df-4e3c-8153-42dead602cca">2.1</linkHtml>)</item>
                           <item>Do not use on face or intertriginous areas. (<linkHtml href="#LINK_702a56b6-b0df-4e3c-8153-42dead602cca">2.1</linkHtml>)</item>
                        </list>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Adult patients</content>: Apply to affected areas 3 times daily. (<linkHtml href="#LINK_e4e34996-0bce-4906-8b22-ea8134e502bc">2.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Pediatric patients</content>: Moisten skin and apply to affected areas twice daily for up to 4 weeks. (<linkHtml href="#LINK_e4e34996-0bce-4906-8b22-ea8134e502bc">2.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_702a56b6-b0df-4e3c-8153-42dead602cca">
                     <id root="7650b060-a371-42ab-93e2-f14083a3460d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1Â Â Â Â Â Â  Important Administration Instructions</title>
                     <text>
                        <paragraph>Fluocinolone acetonide 0.01% topical oil is for topical use only. Not for oral, ophthalmic, or intravaginal use.</paragraph>
                        <paragraph>Apply the least amount of fluocinolone acetonide 0.01% topical oil needed to cover the affected areas. Discontinue use when control of disease is achieved within 2 weeks or contact the healthcare provider if no improvement is seen within 2 weeks. </paragraph>
                        <paragraph>Do not use on the face, axillae, or groin unless directed by the healthcare provider. Do not apply to intertriginous areas due to the increased risk of local adverse reactions <content styleCode="italics">[see Adverse Reactions (6) and Use in Specific Populations (8.4)]</content>. </paragraph>
                        <paragraph>Do not apply to the diaper area; diapers or plastic pants may constitute occlusive use <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>. </paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e4e34996-0bce-4906-8b22-ea8134e502bc">
                     <id root="85305937-889f-4811-982b-d287dae69ab3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2Â Â Â Â Â Â  Recommended Dosage in Adults</title>
                     <text>
                        <paragraph>Apply fluocinolone acetonide 0.01% topical oil as a thin film to the affected areas <content styleCode="bold">three times daily</content>.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_22e9637f-1310-41a2-88c5-9417ea5914c2">
                     <id root="464aa55e-b392-4d16-aab1-7271739e6785"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3Â Â Â Â Â Â  Recommended Dosage in Pediatric
Patients</title>
                     <text>
                        <paragraph>Moisten skin and apply fluocinolone acetonide 0.01% topical oil as a thin film to the affected areas <content styleCode="bold">twice daily for up to four weeks</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_e72ed83a-93a0-4692-bd2d-40ec3977f4a3">
               <id root="f2432da8-8a70-4898-8ab2-b83bbdeec0ae"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Fluocinolone Acetonide 0.01% Topical Oil (Body Oil) is a topical oil containing 0.01% fluocinolone acetonide, supplied in bottles containing 4 fluid ounces.</paragraph>
               </text>
               <effectiveTime value="20250519"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Fluocinolone Acetonide 0.01% Topical Oil (Body Oil) is a topical oil containing 0.01% fluocinolone acetonide supplied in bottles containing 4 fluid ounces. (3)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_0c31c45d-6947-421e-877b-0c482d1351ba">
               <id root="39e60ef3-6acf-4003-9383-017f4e0915c1"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20250519"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None (4).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_8fc8abc2-3ffc-4487-b7f2-eec01933bdcf">
               <id root="1f8046c9-8658-4f57-b23b-f3f403062f69"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20250519"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Endocrine System Adverse Reactions</content>:
    <list listType="unordered" styleCode="Circle">
                                 <item>Topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria. (<linkHtml href="#LINK_1f02f330-514b-4790-bc35-5fc76c917c1f">5.1</linkHtml>)</item>
                                 <item>Pediatric patients may be more susceptible to systemic toxicity from equivalent doses. (<linkHtml href="#LINK_1f02f330-514b-4790-bc35-5fc76c917c1f">5.1</linkHtml>, <linkHtml href="#LINK_c4fa8285-ae1e-427b-9edf-63b2700eba2e">8.4</linkHtml>)</item>
                                 <item>Systemic absorption may require evaluation for HPA axis suppression. </item>
                              </list>
                              <paragraph>Potent corticosteroids use on large areas, prolonged use, occlusive use, altered skin barrier, liver failure, and young age may increase systemic absorption. Modify use should HPA axis suppression develop. (<linkHtml href="#LINK_1f02f330-514b-4790-bc35-5fc76c917c1f">5.1</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <content styleCode="underline">Local Adverse Reactions:</content> Local adverse reactions may include atrophy, striae irritation, acneiform eruptions, hypopigmentation, and allergic contact dermatitis and may be more likely with occlusive use or more potent corticosteroids (<linkHtml href="#LINK_f59b7574-1777-4935-aa00-925d42f2c559">5.2</linkHtml>, <linkHtml href="#LINK_7283fe83-45b0-47ac-a525-660ddd42aac1">6.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Ophthalmic Adverse Reactions</content>: May increase the risks of glaucoma and posterior subcapsular cataract. Avoid contact of Fluocinolone Acetonide 0.01% Topical Oil (Body Oil) with eyes. Advise patients to report any visual symptoms and consider referral to an ophthalmologist for evaluation. (<linkHtml href="#LINK_8872714e-20c3-44d8-96c5-c6dcfb763821">5.3</linkHtml>)</item>
                        </list>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_1f02f330-514b-4790-bc35-5fc76c917c1f">
                     <id root="98a76a8e-b0e6-403e-887a-084e6cf43b1e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1Â Â Â Â Â Â  Endocrine
System Adverse Reactions</title>
                     <text>
                        <paragraph>Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. Cushing's syndrome, hyperglycemia, and glucosuria can result from systemic absorption of topical corticosteroids.</paragraph>
                        <paragraph>HPA axis suppression and Cushingâs syndrome have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and subnormal response to ACTH stimulation. Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios <content styleCode="italics">[see Use in Specific Populations (8.4)]. </content>
                        </paragraph>
                        <paragraph>Conditions which increase systemic absorption include the use of more potent corticosteroids, use over large surface areas, use over prolonged periods, use of occlusive dressings, altered skin barrier, liver failure, and young age. Use of more than one corticosteroid-containing product at the same time may increase total systemic corticosteroid exposure. Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression. The ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression.</paragraph>
                        <paragraph>If HPA axis suppression is documented, reduce the frequency of application or discontinue fluocinolone acetonide 0.01% topical oil, or substitute with a less potent corticosteroid. Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f59b7574-1777-4935-aa00-925d42f2c559">
                     <id root="70a3a6fb-f4b0-425c-a660-896ba0c4ffc5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2Â Â Â Â Â Â  Local Adverse Reactions</title>
                     <text>
                        <paragraph>Local adverse reactions may occur with use of topical corticosteroids, including fluocinolone acetonide 0.01% topical oil, and may be more likely to occur with occlusive use, prolonged use or use of higher potency corticosteroids. Some local adverse reactions may be irreversible. Reactions may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria <content styleCode="italics">[see <linkHtml href="#LINK_7283fe83-45b0-47ac-a525-660ddd42aac1">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_8872714e-20c3-44d8-96c5-c6dcfb763821">
                     <id root="5addc537-fb65-4615-afde-62f59cd622d8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Â Â Â Â Â  Ophthalmic
Adverse Reactions</title>
                     <text>
                        <paragraph>Use of topical corticosteroids may increase the risks of glaucoma and posterior subcapsular cataract. Glaucoma and cataracts have been reported in postmarketing experience with the use of topical corticosteroid products. Avoid contact of fluocinolone acetonide 0.01% topical oil with eyes. Advise patients to report any visual symptoms and consider referral to an ophthalmologist for evaluation. </paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2099687a-1b89-43d2-a44f-78f34d99b950">
                     <id root="d762f94e-dc98-4224-8213-ccaa52b04380"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4Â Â Â Â Â Â  Allergic Contact Dermatitis</title>
                     <text>
                        <paragraph>Use of topical corticosteroids can cause allergic contact dermatitis. Allergic contact dermatitis to any component of topical corticosteroids is usually diagnosed by a failure to heal rather than a clinical exacerbation. Clinical diagnosis of allergic contact dermatitis can be confirmed by patch testing.</paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a068c446-54a4-41bd-a900-071225371f0e">
                     <id root="70eb9018-dab6-4ef6-8cfe-fdeaf1279832"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5Â Â Â Â Â Â  Concomitant Skin Infections</title>
                     <text>
                        <paragraph>Use of topical corticosteroids may delay healing or worsen concomitant skin infections. Treat concomitant skin infections with an appropriate antimicrobial agent. If the infection persists unchanged, discontinue fluocinolone acetonide topical oil 0.01% until the infection has been adequately treated.</paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_79752228-7781-4d12-99ea-9501e4e3598a">
                     <id root="5f05f969-71bc-4d4f-b967-ceb19e3f3c50"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6Â Â Â Â Â Â  Use in Peanut-Sensitive Individuals</title>
                     <text>
                        <paragraph>Use caution in prescribing fluocinolone acetonide 0.01% topical oil for peanut-sensitive individuals <content styleCode="italics">[see Description (11)]</content>. </paragraph>
                        <paragraph>Should signs of hypersensitivity present (wheal and flare reactions, pruritus, or other manifestations), or should disease exacerbations occur, discontinue fluocinolone acetonide 0.01% topical oil immediately and institute appropriate therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_47191684-9b2a-4833-b9c3-fea375dd1862">
               <id root="3769d0a2-5164-45c9-9462-6ae2f44ab762"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious adverse reactions are discussed in more detail in other sections of the labeling: </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Endocrine System Adverse Reactions <content styleCode="italics">[see <linkHtml href="#LINK_1f02f330-514b-4790-bc35-5fc76c917c1f">Warnings and Precautions (5.1)</linkHtml>, <linkHtml href="#LINK_c4fa8285-ae1e-427b-9edf-63b2700eba2e">Use in Specific Populations (8.4)</linkHtml>] </content>
                     </item>
                     <item>Local Adverse Reactions <content styleCode="italics">[see <linkHtml href="#LINK_f59b7574-1777-4935-aa00-925d42f2c559">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Ophthalmic Adverse Reactions <content styleCode="italics">[see <linkHtml href="#LINK_8872714e-20c3-44d8-96c5-c6dcfb763821">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                  </list>
                  <br/>
               </text>
               <effectiveTime value="20250519"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (â¥ 5%) were cough (20%), rhinorrhea (13%), pyrexia (10%), telangiectasia (7%), nasopharyngitis (7%), and hypopigmentation (7%).Â (<linkHtml href="#LINK_7283fe83-45b0-47ac-a525-660ddd42aac1">6.1</linkHtml>, <linkHtml href="#LINK_42778bb8-bd1c-4732-88ac-bc155237d4af">6.2</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">Â </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals LLC at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_7283fe83-45b0-47ac-a525-660ddd42aac1">
                     <id root="57d20735-022d-4760-881d-15d1ccae1348"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1Â Â Â Â Â Â  Clinical Studies Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>An open-label trial was conducted in 58 pediatric subjects 2 years to 12 years of age with moderate to severe atopic dermatitis to evaluate the safety of fluocinolone acetonide 0.01% topical oil when applied to the face twice daily for 4 weeks. Adverse reactions reported by â¥2% of pediatric subjects treated with fluocinolone acetonide 0.01% topical oil are shown in Table 1.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Â </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1: Adverse Reactions in â¥2% of Pediatric Subjects 2 Years to 12 Years of Age with Moderate to Severe Atopic Dermatitis, Treated with Fluocinolone Acetonide 0.01% Topical Oil,</content>
                           <content styleCode="bold">N=58</content>
                        </paragraph>
                        <table width="100%" cellspacing="0" cellpadding="0" border="1">
                           <col width="36%"/>
                           <col width="22.08%"/>
                           <col width="13.98%"/>
                           <col width="13.98%"/>
                           <col width="13.96%"/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction (AR)*</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Day 14</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Day 28â </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Day 56â¡</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Any AE</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>15 (26)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>6 (10)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>7 (12)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>7 (12)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Telangiectasia</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>5 (9)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3 (5)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4 (7)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2 (4)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Erythema</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3 (5)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3 (5)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Itching</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3 (5)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3 (5)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Irritation</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3 (5)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3 (5)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Burning</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3 (5)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3 (5)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Hypopigmentation</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2 (4)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2 (4)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Shiny skin</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Secondary atopic dermatitis</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Papules and pustules</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Keratosis pilaris</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Folliculitis</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Facial herpes simplex</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Acneiform eruption</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Ear infection</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>*The number of individual adverse reactions reported does not necessarily reflect the number of individual subjects, since one subject could have multiple reports of an adverse reaction.</paragraph>
                        <paragraph>
                           <content styleCode="bold">â </content>End of Treatment</paragraph>
                        <paragraph>
                           <content styleCode="bold">â¡</content>Four Weeks Post Treatment</paragraph>
                        <paragraph>An open-label safety trial was conducted in 29 pediatric subjects 3 months to 2 years of age to assess the HPA axis by ACTH stimulation testing following use of fluocinolone acetonide 0.01% topical oil twice daily for 4 weeks. The trial included 7 subjects ages 3 to 6 months, 7 subjects ages &gt; 6 to 12 months, and 15 subjects ages &gt; 12 months to 2 years. All subjects had moderate to severe atopic dermatitis with disease involvement on at least 20% body surface area (BSA). Eleven (11) subjects had baseline BSA involvement of 50% to 75% and 7 subjects had BSA involvement of greater than 75% <content styleCode="italics">[see Use in Specific Populations (8.4)].</content> The most common adverse reactions reported in the study (â¥2%) are shown in Table 2. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Â </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 2: Adverse Reactions in â¥ 2% of Pediatric Subjects 3 Months to 2 Years of Age with Moderate to Severe Atopic Dermatitis, Treated with Fluocinolone Acetonide 0.01% Topical Oil, N=30*</content>
                        </paragraph>
                        <table width="100%" cellspacing="0" cellpadding="0" border="1">
                           <col width="54.72%"/>
                           <col width="45.28%"/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Cough</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>6 (20)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Rhinorrhea</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4 (13)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Pyrexia</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3 (10)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Nasopharyngitis</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2 (7)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Hypopigmentation</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2 (7)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Abscess</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Atopic Dermatitis</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Eczema</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Hyperpigmentation</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Molluscum</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Rash</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Diarrhea</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Otitis Media</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>URI</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Vomiting</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (3)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>*Includes one subject who withdrew at Week 2</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_42778bb8-bd1c-4732-88ac-bc155237d4af">
                     <id root="388493bf-815f-4da7-b2f6-cd42a15e7526"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of products containing topical corticosteroids. Because postmarketing adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Endocrine Disorders: HPA axis suppression and Cushingâs syndrome <content styleCode="italics">[see Use in Specific Populations (8.4)]</content>
                           </item>
                           <item>Eye Disorders: glaucoma and cataracts <content styleCode="italics">[see Warnings and Precautions (5.3)]</content>
                           </item>
                           <item>Nervous System Disorders: intracranial hypertension including bulging fontanelles, headaches, and bilateral papilledema<content styleCode="italics"> [see Use in Specific Populations (8.4)]</content>
                           </item>
                        </list>
                        <br/>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_89c8ea8e-bca3-4887-b737-f22761ca9b80">
               <id root="ce014dd1-7b74-4099-9517-493d1c9dcd1b"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20250519"/>
               <component>
                  <section ID="LINK_a5cc5456-2fc5-4095-b41b-6009cc71135a">
                     <id root="db95148a-1d2a-494c-bd34-9dc05d8fd4b5"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Available data from case reports, case series, and observational studies on fluocinolone acetonide use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Observational studies suggest maternal use of high to super-high potency topical steroids may be associated with an increased risk of low birthweight infants. Advise pregnant women to use fluocinolone acetonide 0.01% topical oil on the smallest area of skin and for the shortest duration possible. </paragraph>
                        <paragraph>Corticosteroids can cause fetal malformations in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids cause fetal malformations after dermal application in laboratory animals. </paragraph>
                        <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. </paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_95f8066d-cdda-425e-a297-97ed20f2eec8">
                     <id root="ac53eff0-5280-4784-9dd4-e09ded0601d2"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2Â Â Â Â Â Â  Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There is no information regarding the presence of fluocinolone acetonide in breast milk or its effects on the breastfed infant or on milk production. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. To minimize potential exposure to the breastfed infant via breast milk, use fluocinolone acetonide 0.01% topical oil on the smallest area of skin and for the shortest duration possible while breastfeeding. Advise breastfeeding women not to apply fluocinolone acetonide 0.01% topical oil directly to the nipple and areola to avoid direct infant exposure<content styleCode="italics"> [see Warnings and Precautions (5.1) and Use in Specific Populations (8.4)]. </content>The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for fluocinolone acetonide 0.01% topical oil and any potential adverse effects on the breastfed infant from fluocinolone acetonide 0.01% topical oil or from the underlying maternal condition. </paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c4fa8285-ae1e-427b-9edf-63b2700eba2e">
                     <id root="6caff270-598e-494c-8384-ac7ecf7872c9"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of fluocinolone acetonide 0.01% topical oil for the topical treatment of moderate to severe atopic dermatitis have been established in pediatric patients aged 3 months and older for up to 4 weeks. </paragraph>
                        <paragraph>Safety and effectiveness of fluocinolone acetonide 0.01% topical oil in pediatric patients with atopic dermatitis below the age of 3 months have not been established. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Systemic Adverse Reactions in Pediatric Patients</content>
                           </content>
                        </paragraph>
                        <paragraph>HPA axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and subnormal response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.</paragraph>
                        <paragraph>Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk for systemic adverse reactions than are adults when treated with topical corticosteroids <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Evaluation in Peanut-Sensitive Pediatric Patients</content>
                           </content>
                        </paragraph>
                        <paragraph>A clinical trial was conducted to assess the safety of fluocinolone acetonide 0.01% topical oil, which contains refined peanut oil, on pediatric subjects with known peanut allergies. The study enrolled 13 pediatric subjects with atopic dermatitis, 6 to 17 years of age. Of the 13 subjects, 9 were Radioallergosorbent Test (RAST) positive to peanuts and 4 had no peanut sensitivity (controls). The trial evaluated the subjectsâ responses to both prick test and patch test utilizing refined peanut oil NF, fluocinolone acetonide 0.01% topical oil and histamine/saline controls. Subjects were also treated with fluocinolone acetonide topical oil 0.01% twice daily for 7 days. Prick test and patch test results for all 13 patients were negative to fluocinolone acetonide 0.01% topical oil and the refined peanut oil. One of the 9 peanut-sensitive patients experienced an exacerbation of atopic dermatitis after 5 days of fluocinolone acetonide 0.01% topical oil. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Evaluation in Pediatric Patients 2 to 6 years old</content>
                           </content>
                           <br/>
Use of fluocinolone acetonide 0.01% topical oil in pediatric patients 2 to 6 years old is supported by open-label safety trials conducted in 33 pediatric subjects (20 subjects ages 2 to 6 years, 13 subjects ages 7 to 12 years) with moderate to severe stable atopic dermatitis. Baseline body surface area involvement was 50% to 75% in 15 subjects and greater than 75% in 18 subjects. Subjects were treated with fluocinolone acetonide 0.01% topical oil twice daily for 4 weeks. Morning pre-stimulation cortisol and post-ACTH stimulation cortisol levels were obtained in each subject at the beginning of the trial and at the end of 4 weeks of treatment. At the end of treatment, 4 out of 18 subjects aged 2 to 5 years showed low pre-stimulation cortisol levels (3.2 to 6.6 mcg/dL; normal: cortisol &gt; 7 mcg/dL) but all had normal responses to 0.25 mg of ACTH stimulation (cortisol &gt; 18 mcg/dL) <content styleCode="italics">[see Clinical Pharmacology (12.2)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Evaluation in Pediatric Patients 3 months to 2 years old</content>
                           </content>
                        </paragraph>
                        <paragraph>Use of fluocinolone acetonide 0.01% topical oil in pediatric patients 3 months to 2 years old is supported by an open-label safety trial conducted in 29 pediatric subjects (7 subjects ages 3 to 6 months, 7 subjects ages &gt; 6 to 12 months, and 15 subjects ages &gt; 12 months to 2 years) to assess the HPA axis by ACTH stimulation testing following use of fluocinolone acetonide 0.01% topical oil twice daily for 4 weeks <content styleCode="italics">[see Adverse Reactions (6.1)]</content>. Morning pre-stimulation and post-ACTH stimulation cortisol levels were obtained in each subject at the beginning of the trial and at the end of 4 weeks of treatment. All subjects had normal responses to 0.125 mg of ACTH stimulation (cortisol &gt; 18 mcg/dL) <content styleCode="italics">[see Clinical Pharmacology (12.2)]</content>.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_33814d9e-a00c-4b00-9b9a-f701ddbf6f24">
               <id root="d75f4757-96cc-4f2b-952e-7e5e8564151a"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Fluocinolone Acetonide 0.01% Topical Oil (Body Oil) contains fluocinolone acetonide [(6Î±, 11Î², 16Î±)-6,9-difluoro-11,21-dihydroxy-16,17[(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione, cyclic 16,17 acetal with acetone], a synthetic corticosteroid for topical dermatologic use. This formulation is also marketed as Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil) for use with shower caps for treatment of scalp psoriasis in adults and as fluocinolone acetonide oil, 0.01% for treatment of chronic eczematous external otitis. Chemically, fluocinolone acetonide is C<sub>24</sub> H<sub>30</sub> F<sub>2</sub> O<sub>6</sub>. It has the following structural formula:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Fluocinolone acetonide in Fluocinolone Acetonide 0.01% Topical Oil has a molecular weight of 452.50. It is a white crystalline powder that is odorless, stable in light, and melts at 270Â°C with decomposition; soluble in alcohol, acetone and methanol; slightly soluble in chloroform; insoluble in water.</paragraph>
                  <paragraph>Each gram of Fluocinolone Acetonide 0.01% Topical Oil contains approximately 0.11 mg of fluocinolone acetonide in a blend of oils, which contains isopropyl alcohol, isopropyl myristate, light mineral oil, oleth-2, and refined peanut oil NF.</paragraph>
                  <paragraph>Fluocinolone Acetonide 0.01% Topical Oil is formulated with 48% refined peanut oil NF. Physicians should use caution in prescribing Fluocinolone Acetonide 0.01% Topical Oil for peanut-sensitive individuals. </paragraph>
               </text>
               <effectiveTime value="20250519"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fluocinolone-acetonide-0-01-percent-topical-oil-bo-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_c5042062-5c28-4c6f-9447-c988bbbfe723">
               <id root="92694be0-64a0-4d3f-a854-227524a20f1b"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250519"/>
               <component>
                  <section ID="LINK_b9159e0c-fb84-4e60-be8d-98f99a1e4c5d">
                     <id root="bc80e9b1-f7ea-46f2-ba68-9b381b648af3"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in atopic dermatitis is unknown.Â </paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5dfaa6e8-e7ea-4a16-9782-590570a46a9b">
                     <id root="8f245654-08d4-4b22-a1f8-018c6bf26972"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Vasoconstrictor Assay</content>
                        </paragraph>
                        <paragraph>Fluocinolone acetonide 0.01% topical oil is in the low to medium range of potency as compared with other topical corticosteroids in vasoconstrictor studies. However, similar blanching scores do not necessarily imply therapeutic equivalence. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression</content>
                        </paragraph>
                        <paragraph>HPA axis suppression was evaluated in 29 pediatric subjects 3 months to 2 years old (7 subjects ages 3 to 6 months, 7 subjects ages &gt; 6 to 12 months, and 15 subjects ages &gt; 12 months to 2 years) and 33 pediatric subjects 2 years to 12 years old (20 subjects ages 2 to 6 years, 13 subjects ages 7 to 12 years) with moderate to severe atopic dermatitis. Subjects were treated with Fluocinolone acetonide 0.01% topical oil twice daily for 4 weeks. Morning pre-stimulation and post-ACTH stimulation cortisol levels were obtained in each subject at the beginning of the trial and at the end of 4 weeks of treatment. In subjects 3 months to 2 years old, all subjects had normal responses to 0.125 mg of ACTH stimulation (cortisol &gt; 18 mcg/dL). In subjects 2 to 12 years old, 4 out of 18 subjects 2 to 5 years old showed low pre-stimulation cortisol levels (3.2 to 6.6 mcg/dL; normal: cortisol &gt; 7mcg/dL) but all had normal responses to 0.25 mg of ACTH stimulation (cortisol &gt; 18 mcg/dL) at the end of treatment<content styleCode="italics"> [see Warnings and Precautions (5.1) and Use in Specific Populations (8.4)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e8886aac-ab0f-4b04-a6a5-c7631e43e4c6">
                     <id root="5007514e-c2c3-43ae-90d1-13940993f852"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the product formulation and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may increase percutaneous absorption. The use of pharmacodynamic endpoints for assessing the systemic exposure of topical corticosteroids may be necessary due to the fact that circulating levels are often below the level of detection. Once absorbed through the skin, topical corticosteroids are metabolized, primarily in the liver, and are then excreted by the kidneys. Some corticosteroids and their metabolites are also excreted in the bile.</paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_f3f917db-9722-401d-bdf4-b2c4b19a849f">
               <id root="b95c6f57-73a1-4168-a545-bdd502f720b9"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250519"/>
               <component>
                  <section ID="LINK_caa82b00-f125-47a9-a51e-76f360bde2c7">
                     <id root="66d6aba1-2cc0-4029-b7f3-210a249fa84a"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis and Mutagenesis and Impairment of Fertility</title>
                     <text>
                        <paragraph>No carcinogenicity, genotoxicity, or fertility studies were conducted with fluocinolone acetonide 0.01% topical oil. However, some corticosteroids are genotoxic in various genotoxicity tests (i.e., the <content styleCode="italics">in vitro</content> human peripheral blood lymphocyte chromosome aberration assay with metabolic activation, the <content styleCode="italics">in vivo</content> mouse bone marrow micronucleus assay, the Chinese hamster micronucleus test, and the <content styleCode="italics">in vitro</content> mouse lymphoma gene mutation assay).</paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_082b16e2-44bd-411f-a64a-d105bdafaff2">
               <id root="d40eea29-4c8c-45ce-95ad-6428ad295fb3"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIEDÂ Â / STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Fluocinolone Acetonide 0.01% Topical Oil (Body Oil) is supplied in bottles containing 4 fluid ounces (NDC 65162-704-86).</paragraph>
                  <paragraph>Storage: Keep tightlyclosed. Store upright at 20Â° to 25Â°C (68Â° to 77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) [see USP Controlled Room Temperature].</paragraph>
               </text>
               <effectiveTime value="20250519"/>
            </section>
         </component>
         <component>
            <section ID="LINK_7c856679-7176-4538-b26d-22c9318fbdc5">
               <id root="b459cec8-9902-492e-a92d-96d30d64658d"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Administration Instructions</content>
                  </paragraph>
                  <paragraph>Advise patients that fluocinolone acetonide 0.01% topical oil is for topical use only <content styleCode="italics">[see Dosage and Administration (2.1)].</content>
                  </paragraph>
                  <paragraph>Advise patients not to apply fluocinolone acetonide 0.01% topical oil under occlusion unless directed by their healthcare provider. Instruct patients not to apply fluocinolone acetonide 0.01% topical oil to the diaper area as diapers or plastic pants may constitute occlusive use <content styleCode="italics">[see Dosage and Administration (2.1)]</content>.</paragraph>
                  <paragraph>Advise patients to avoid use of fluocinolone acetonide 0.01% topical oil on the face, axillae, or groin unless directed by their healthcare provider <content styleCode="italics">[see Dosage and Administration (2.1)]</content>.</paragraph>
                  <paragraph>Advise patients to discontinue therapy when control of disease is achieved. Instruct patients to contact their healthcare provider if no improvement is seen within 2 weeks <content styleCode="italics">[see Dosage and Administration (2.1)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Endocrine System Adverse Reactions</content>
                  </paragraph>
                  <paragraph>Instruct patients not to use other corticosteroid-containing products while using fluocinolone acetonide 0.01% topical oil without first consulting their healthcare provider <content styleCode="italics">[see Warnings and Precautions (5.1)]. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Ophthalmic Adverse Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients to avoid contact with the eyes and in case of contact, wash eyes liberally with water. Instruct patients to tell their healthcare provider if they develop any visual symptoms <content styleCode="italics">[see Warnings and Precautions (5.3)]. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Pregnancy and Lactation</content>
                  </paragraph>
                  <paragraph>Advise patients to use fluocinolone acetonide 0.01% topical oil on the smallest area of skin and for the shortest duration possible while pregnant or breastfeeding. Advise patients that are breastfeeding not to apply fluocinolone acetonide 0.01% topical oil directly to the nipple and areola to avoid direct infant exposure <content styleCode="italics">[see Use in Specific Populations (8.1 and 8.2)]. </content>
                  </paragraph>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Amneal Pharmaceuticals LLC</content>
                  </paragraph>
                  <paragraph>Bridgewater, NJÂ  08807</paragraph>
                  <paragraph>Rev. 05-2025-01</paragraph>
               </text>
               <effectiveTime value="20250519"/>
            </section>
         </component>
         <component>
            <section ID="LINK_387cc7b8-77cb-4fcc-8f94-b4997ccf5b3f">
               <id root="c0baade3-59e5-448d-bc82-ef0a0b795d98"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM2"/>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20250519"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>ifc</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fluocinolone-acetonide-0-01-percent-topical-oil-bo-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>